{"id":59236,"date":"2026-03-11T13:28:24","date_gmt":"2026-03-11T05:28:24","guid":{"rendered":"https:\/\/flcube.com\/?p=59236"},"modified":"2026-03-11T13:28:25","modified_gmt":"2026-03-11T05:28:25","slug":"fda-approves-gsks-wellcovorin-for-cerebral-folate-deficiency-first-treatment-for-rare-folr1-genetic-disorder","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59236","title":{"rendered":"FDA Approves GSK’s Wellcovorin for Cerebral Folate Deficiency \u2013 First Treatment for Rare FOLR1 Genetic Disorder"},"content":{"rendered":"\n

The U.S. Food and Drug Administration (FDA)<\/strong> approved expanded use<\/strong> of GlaxoSmithKline’s<\/strong> (GSK, NYSE: GSK<\/a>) Wellcovorin (leucovorin calcium)<\/strong> tablets for the treatment of cerebral folate deficiency (CFD)<\/strong> in adult and pediatric patients<\/strong> with confirmed variants in the folate receptor 1 gene (CFD-FOLR1)<\/strong>. The approval, based on systematic literature review<\/strong> including published case reports and mechanistic data<\/strong>, marks the first FDA-approved therapy<\/strong> for this ultra-rare neurological disorder<\/strong> characterized by severe developmental delays, movement disorders, seizures, and other serious complications<\/strong> due to impaired brain folate transport.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>U.S. Food and Drug Administration (FDA)<\/td><\/tr>
Approval Type<\/strong><\/td>Label expansion (new indication)<\/td><\/tr>
Product<\/strong><\/td>Wellcovorin (leucovorin calcium) tablets<\/td><\/tr>
New Indication<\/strong><\/td>Cerebral folate deficiency (CFD) \u2013 FOLR1 variant<\/td><\/tr>
Patient Population<\/strong><\/td>Adult and pediatric patients with confirmed CFD-FOLR1<\/td><\/tr>
Prior Approvals<\/strong><\/td>Folinic acid rescue after high-dose methotrexate; colorectal cancer adjuvant therapy<\/td><\/tr>
Approval Basis<\/strong><\/td>Systematic literature review; published case reports; mechanistic data (no new clinical trials)<\/td><\/tr>
Significance<\/strong><\/td>First FDA-approved treatment for CFD-FOLR1<\/strong><\/td><\/tr>
Approval Date<\/strong><\/td>10\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Disease Profile & Unmet Need<\/h2>\n\n\n\n
Attribute<\/th>Cerebral Folate Deficiency (CFD-FOLR1) Specification<\/th><\/tr><\/thead>
Mechanism<\/strong><\/td>Genetic variants in FOLR1 gene impair folate receptor alpha function<\/td><\/tr>
Pathophysiology<\/strong><\/td>Disrupted active transport of folate across blood-brain barrier<\/td><\/tr>
Clinical Manifestations<\/strong><\/td>\u2022 Severe developmental delays
\u2022 Movement disorders (dystonia, ataxia)
\u2022 Seizures
\u2022 Other serious neurological complications<\/td><\/tr>
Prevalence<\/strong><\/td>Ultra-rare; exact incidence unknown; estimated <1,000 U.S. patients<\/td><\/tr>
Prior Treatment<\/strong><\/td>No FDA-approved options; off-label folinic acid\/leucovorin used empirically<\/td><\/tr>
Diagnostic Challenge<\/strong><\/td>Requires genetic confirmation; often misdiagnosed as cerebral palsy or mitochondrial disorders<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile & Mechanism<\/h2>\n\n\n\n
Attribute<\/th>Wellcovorin (Leucovorin Calcium) Specification<\/th><\/tr><\/thead>
Drug Class<\/strong><\/td>Folinic acid (5-formyltetrahydrofolate) \u2013 active folate metabolite<\/td><\/tr>
Mechanism in CFD<\/strong><\/td>Bypasses defective FOLR1-mediated transport; provides bioavailable folate for CNS metabolism<\/td><\/tr>
Formulation<\/strong><\/td>Oral tablets<\/td><\/tr>
Route Advantage<\/strong><\/td>Oral vs. intrathecal folate injections (previously required in severe cases)<\/td><\/tr>
Safety Profile<\/strong><\/td>Well-established; decades of use in oncology and methotrexate rescue<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Context & Market Impact<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
Orphan Drug Dynamics<\/strong><\/td>Ultra-rare indication supports premium pricing; potential priority review voucher eligibility<\/td><\/tr>
Literature-Based Approval<\/strong><\/td>FDA leveraging real-world evidence and mechanistic rationale accelerates access for desperate patients<\/td><\/tr>
GSK Rare Disease<\/strong><\/td>Expands neurology\/metabolic franchise; complements gene therapy pipeline<\/td><\/tr>
Patient Advocacy<\/strong><\/td>First approved therapy validates patient\/family advocacy efforts; diagnostic testing likely to increase<\/td><\/tr>
Global Expansion<\/strong><\/td>EMA, PMDA filings anticipated; Orphan Drug Designation in other regions probable<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Regulatory Precedent<\/h2>\n\n\n\n
Aspect<\/th>Significance<\/th><\/tr><\/thead>
Evidence Standard<\/strong><\/td>Systematic literature review + case series sufficient for approval in ultra-rare, life-threatening conditions<\/td><\/tr>
Mechanistic Rationale<\/strong><\/td>Strong biological plausibility (folate bypass) supported approval without controlled trials<\/td><\/tr>
FDA Flexibility<\/strong><\/td>Demonstrates willingness to approve based on natural history data and treatment response in rare diseases<\/td><\/tr>
Template for Future<\/strong><\/td>May accelerate approvals for other metabolic disorders with clear mechanistic targets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding commercial launch execution, pricing strategy, and global regulatory expansion for Wellcovorin in cerebral folate deficiency. Actual results may differ due to diagnostic testing rates, reimbursement negotiations, and competitive dynamics in the rare disease metabolic space.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

The U.S. Food and Drug Administration (FDA) approved expanded use of GlaxoSmithKline’s (GSK, NYSE: GSK)…<\/p>\n","protected":false},"author":1,"featured_media":59239,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[278,184,914,15,24],"class_list":["post-59236","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-glaxosmithkline","tag-gsk","tag-nyse-gsk","tag-product-approvals","tag-rare-orphan-disease-drugs"],"yoast_head":"\nFDA Approves GSK's Wellcovorin for Cerebral Folate Deficiency \u2013 First Treatment for Rare FOLR1 Genetic Disorder - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The U.S. Food and Drug Administration (FDA) approved expanded use of GlaxoSmithKline's (GSK, NYSE: GSK) Wellcovorin (leucovorin calcium) tablets for the treatment of cerebral folate deficiency (CFD) in adult and pediatric patients with confirmed variants in the folate receptor 1 gene (CFD-FOLR1). The approval, based on systematic literature review including published case reports and mechanistic data, marks the first FDA-approved therapy for this ultra-rare neurological disorder characterized by severe developmental delays, movement disorders, seizures, and other serious complications due to impaired brain folate transport.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59236\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Approves GSK's Wellcovorin for Cerebral Folate Deficiency \u2013 First Treatment for Rare FOLR1 Genetic Disorder\" \/>\n<meta property=\"og:description\" content=\"The U.S. Food and Drug Administration (FDA) approved expanded use of GlaxoSmithKline's (GSK, NYSE: GSK) Wellcovorin (leucovorin calcium) tablets for the treatment of cerebral folate deficiency (CFD) in adult and pediatric patients with confirmed variants in the folate receptor 1 gene (CFD-FOLR1). The approval, based on systematic literature review including published case reports and mechanistic data, marks the first FDA-approved therapy for this ultra-rare neurological disorder characterized by severe developmental delays, movement disorders, seizures, and other serious complications due to impaired brain folate transport.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59236\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-11T05:28:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-11T05:28:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1102.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59236#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59236\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"FDA Approves GSK’s Wellcovorin for Cerebral Folate Deficiency \u2013 First Treatment for Rare FOLR1 Genetic Disorder\",\"datePublished\":\"2026-03-11T05:28:24+00:00\",\"dateModified\":\"2026-03-11T05:28:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59236\"},\"wordCount\":495,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59236#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1102.webp\",\"keywords\":[\"GlaxoSmithKline\",\"GSK\",\"NYSE: GSK\",\"Product approvals\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59236#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59236\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59236\",\"name\":\"FDA Approves GSK's Wellcovorin for Cerebral Folate Deficiency \u2013 First Treatment for Rare FOLR1 Genetic Disorder - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59236#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59236#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1102.webp\",\"datePublished\":\"2026-03-11T05:28:24+00:00\",\"dateModified\":\"2026-03-11T05:28:25+00:00\",\"description\":\"The U.S. Food and Drug Administration (FDA) approved expanded use of GlaxoSmithKline's (GSK, NYSE: GSK) Wellcovorin (leucovorin calcium) tablets for the treatment of cerebral folate deficiency (CFD) in adult and pediatric patients with confirmed variants in the folate receptor 1 gene (CFD-FOLR1). The approval, based on systematic literature review including published case reports and mechanistic data, marks the first FDA-approved therapy for this ultra-rare neurological disorder characterized by severe developmental delays, movement disorders, seizures, and other serious complications due to impaired brain folate transport.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59236#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59236\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59236#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1102.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1102.webp\",\"width\":1080,\"height\":608,\"caption\":\"FDA Approves GSK's Wellcovorin for Cerebral Folate Deficiency \u2013 First Treatment for Rare FOLR1 Genetic Disorder\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59236#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Approves GSK’s Wellcovorin for Cerebral Folate Deficiency \u2013 First Treatment for Rare FOLR1 Genetic Disorder\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA Approves GSK's Wellcovorin for Cerebral Folate Deficiency \u2013 First Treatment for Rare FOLR1 Genetic Disorder - Insight, China's Pharmaceutical Industry","description":"The U.S. Food and Drug Administration (FDA) approved expanded use of GlaxoSmithKline's (GSK, NYSE: GSK) Wellcovorin (leucovorin calcium) tablets for the treatment of cerebral folate deficiency (CFD) in adult and pediatric patients with confirmed variants in the folate receptor 1 gene (CFD-FOLR1). The approval, based on systematic literature review including published case reports and mechanistic data, marks the first FDA-approved therapy for this ultra-rare neurological disorder characterized by severe developmental delays, movement disorders, seizures, and other serious complications due to impaired brain folate transport.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59236","og_locale":"en_US","og_type":"article","og_title":"FDA Approves GSK's Wellcovorin for Cerebral Folate Deficiency \u2013 First Treatment for Rare FOLR1 Genetic Disorder","og_description":"The U.S. Food and Drug Administration (FDA) approved expanded use of GlaxoSmithKline's (GSK, NYSE: GSK) Wellcovorin (leucovorin calcium) tablets for the treatment of cerebral folate deficiency (CFD) in adult and pediatric patients with confirmed variants in the folate receptor 1 gene (CFD-FOLR1). The approval, based on systematic literature review including published case reports and mechanistic data, marks the first FDA-approved therapy for this ultra-rare neurological disorder characterized by severe developmental delays, movement disorders, seizures, and other serious complications due to impaired brain folate transport.","og_url":"https:\/\/flcube.com\/?p=59236","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-11T05:28:24+00:00","article_modified_time":"2026-03-11T05:28:25+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1102.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59236#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59236"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"FDA Approves GSK’s Wellcovorin for Cerebral Folate Deficiency \u2013 First Treatment for Rare FOLR1 Genetic Disorder","datePublished":"2026-03-11T05:28:24+00:00","dateModified":"2026-03-11T05:28:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59236"},"wordCount":495,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=59236#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1102.webp","keywords":["GlaxoSmithKline","GSK","NYSE: GSK","Product approvals","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59236#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59236","url":"https:\/\/flcube.com\/?p=59236","name":"FDA Approves GSK's Wellcovorin for Cerebral Folate Deficiency \u2013 First Treatment for Rare FOLR1 Genetic Disorder - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=59236#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=59236#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1102.webp","datePublished":"2026-03-11T05:28:24+00:00","dateModified":"2026-03-11T05:28:25+00:00","description":"The U.S. Food and Drug Administration (FDA) approved expanded use of GlaxoSmithKline's (GSK, NYSE: GSK) Wellcovorin (leucovorin calcium) tablets for the treatment of cerebral folate deficiency (CFD) in adult and pediatric patients with confirmed variants in the folate receptor 1 gene (CFD-FOLR1). The approval, based on systematic literature review including published case reports and mechanistic data, marks the first FDA-approved therapy for this ultra-rare neurological disorder characterized by severe developmental delays, movement disorders, seizures, and other serious complications due to impaired brain folate transport.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59236#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59236"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=59236#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1102.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1102.webp","width":1080,"height":608,"caption":"FDA Approves GSK's Wellcovorin for Cerebral Folate Deficiency \u2013 First Treatment for Rare FOLR1 Genetic Disorder"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59236#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"FDA Approves GSK’s Wellcovorin for Cerebral Folate Deficiency \u2013 First Treatment for Rare FOLR1 Genetic Disorder"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1102.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59236","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59236"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59236\/revisions"}],"predecessor-version":[{"id":59240,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59236\/revisions\/59240"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/59239"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59236"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59236"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59236"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}